Tricol Biomedical

Executive Summary

Tricol Biomedical is a privately held medical device company based in Portland, Oregon, dedicated to advancing hemostatic and wound care management. Founded in 2003, the company leverages its proprietary Chito+ chitosan technology to develop products aimed at achieving zero preventable deaths from blood loss. Its integrated approach spans product development, manufacturing, and commercialization, targeting a broad array of clinical settings including emergency medicine, surgery, and military applications. The company's focus on chitosan-based hemostatics addresses a critical need in both civilian and combat trauma care, where rapid bleeding control can significantly improve survival rates.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for next-generation Chito+ hemostatic dressing70% success
• Q2 2027Strategic partnership with a major hospital group for product distribution60% success
• Q3 2027Publication of pivotal clinical trial data for chitosan wound dressing in chronic wounds55% success